00:28:30 EDT Fri 25 Sep 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Microbix Biosystems Inc
Symbol MBX
Shares Issued 108,747,705
Close 2020-06-04 C$ 0.32
Recent Sedar Documents

Microbix signs U.S. distribution deal with Alpha-Tec

2020-06-04 07:53 ET - News Release

Mr. Phil Casselli reports

MICROBIX ANNOUNCES QUALITY PRODUCTS DISTRIBUTION AGREEMENT

Microbix Biosystems Inc. has appointed Alpha-Tec Systems Inc., a Calibre Scientific Inc. firm, as distributor of its quality assessment products for the United States.

Under an agreement between the parties, Alpha-Tec will provide physical distribution, sales and marketing, and technical support for the entire range of Microbix's QAPs -- including its whole-genome controls for molecular testing for COVID-19 disease (caused by the SARS-CoV-2 virus) that are compatible with commercial lab instrument, lab-developed manual and point-of-care-based test systems. Notably, Microbix's REDx FLOQ SARS-CoV-2 is the only RT-PCR test control available on a COPAN FLOQSwab -- enabling ambient-temperature shipping and storage to maximize user convenience, while also supporting workflow from patient-sample receipt through to readout. More broadly, there are four dozen such QAPs across the PROCEEDx, REDx controls and REDx FLOQ trade names -- to support whole-process accuracy of tests for bacterial and viral diseases by emulating patient samples while being consistent, non-infectious, stable and cross-instrument compatible.

Alpha-Tec was founded in 1979 and in 2017 joined Calibre Scientific Inc., a family of companies that provide reagents, tools, instruments and other consumables that address unique needs of the laboratory research, diagnostics, industrial and biopharmaceutical industries in over 50 countries. Alpha-Tec has developed intimate relationships with the clinical laboratory market across the United States, including with independent chains, hospitals, diagnostics companies and research institutions. Alpha-Tec has a highly engaged customer base for its range of products that support bacteriology, mycobacteriology, mycology and parasitology. Microbix's QAPs line is a complementary addition to an Alpha-Tec portfolio that already consists of its QC1 line of validation tools for traditional microbial pathogen testing. The combination is expected to be needed and well received by its existing customer base.

Phil Casselli, senior vice-president of sales and business development of Microbix, commented: "The United States has the potential to become the largest market for our QAPs, so we've sought to find the right distribution partner. We're therefore pleased to have established this relationship with Alpha-Tec. Our COVID-19 and HPV REDx QAPs are now available for the U.S., and Alpha-Tec has the team and relationships needed to make certain Microbix's QAPs become widely used by health care organizations throughout the country."

Chris Williams, general manager of Alpha-Tec, also commented: "The COVID-19 pandemic has made everyone far more aware of the potentially grave consequences of inaccurate testing for infectious diseases. We believe that products which help labs avoid both false-negative and false-positive results are very much needed. We're therefore very pleased to be able to provide Microbix's innovative test controls to our clinical laboratory and hospital customers, certainly for COVID-19 but equally for Microbix's other current or emerging QAPs."

About Microbix Biosystems Inc.

Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now usually exceeding $1-million per month on average.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.